Tasly Pharmaceutical Group Co., Ltd (SHA:600535)
China flag China · Delayed Price · Currency is CNY
13.97
-0.04 (-0.29%)
Sep 15, 2026, 3:00 PM CST

SHA:600535 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
8,0628,1478,4688,6368,6067,898
Other Revenue
87.8289.129.8137.7131.1953.86
8,1498,2368,4988,6748,6377,952
Revenue Growth
-3.15%-3.08%-2.03%0.42%8.62%-41.43%
Cost of Revenue
2,6222,7432,8102,8853,1472,682
Gross Profit
5,5285,4945,6885,7895,4905,269
Selling, General & Admin
3,1623,3063,3343,3263,2673,339
Research & Development
636.82685.66830.07917.27845.34579.53
Other Operating Expenses
134.45105.8287.9896.4637.96110.64
Operating Expenses
3,9364,1184,2524,3484,1494,027
Operating Income
1,5921,3751,4371,4411,3411,243
Interest Expense
-20.24-32.5-61.28-82.52-64.86-77.39
Interest & Investment Income
55.2258.3491.05107.55107.551,792
Currency Exchange Gain (Loss)
0.31-1.06-1.07-1.23-1.617.27
Other Non Operating Income (Expenses)
-9.43-14.74-4.37-4.73-71.110
EBT Excluding Unusual Items
1,6181,3851,4611,4601,3112,965
Impairment of Goodwill
---15.88--151.2-
Gain (Loss) on Sale of Investments
-130.73-31.35-213.45-282.81-1,125-79.88
Gain (Loss) on Sale of Assets
2.038.612.110.15-4.9341.27
Asset Writedown
-56.95-56.95-202.13-1.78-194.64-262.53
Other Unusual Items
54.7739.6736.7845.51-1.9660.04
Pretax Income
1,4871,3451,0691,221-167.632,724
Income Tax Expense
330.84283.89209.63204.46180.82315.92
Earnings From Continuing Operations
1,1561,061859.061,017-348.462,408
Minority Interest in Earnings
66.8543.6396.5354.4384.22-48.75
Net Income
1,2231,105955.591,071-264.242,359
Net Income to Common
1,2231,105955.591,071-264.242,359
Net Income Growth
14.51%15.63%-10.78%--109.51%
Shares Outstanding (Basic)
1,4961,4941,4941,4881,4681,502
Shares Outstanding (Diluted)
1,4961,4941,4941,4881,4681,502
Shares Change
0.66%-0.43%1.34%-2.29%0.08%
EPS (Basic)
0.820.740.640.72-0.181.57
EPS (Diluted)
0.820.740.640.72-0.181.57
EPS Growth
13.76%15.63%-11.16%--109.33%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
1,5401,0431,4501,9071,8752,229
Free Cash Flow Per Share
1.030.700.971.281.281.48
Dividend Per Share
0.3400.3100.5300.3300.3300.330
Dividend Growth
-29.17%-41.51%60.61%0%0%0%
Gross Margin
67.83%66.70%66.94%66.74%63.56%66.27%
Operating Margin
19.54%16.70%16.91%16.61%15.52%15.63%
Profit Margin
15.01%13.41%11.24%12.35%-3.06%29.66%
Free Cash Flow Margin
18.90%12.67%17.06%21.98%21.71%28.04%
EBITDA
1,9481,7481,9331,9461,7741,648
EBITDA Margin
23.90%21.23%22.75%22.43%20.54%20.72%
D&A For EBITDA
355.75373.14496.2504.91433.92405.08
EBIT
1,5921,3751,4371,4411,3411,243
EBIT Margin
19.54%16.70%16.91%16.61%15.52%15.63%
Effective Tax Rate
22.25%21.10%19.62%16.74%-11.60%
Revenue as Reported
8,1498,2368,4988,6748,637-